Q
26.58
2.23 (9.16%)
| Previous Close | 24.35 |
| Open | 24.53 |
| Volume | 1,911,492 |
| Avg. Volume (3M) | 1,428,964 |
| Market Cap | 1,805,620,224 |
| Price / Earnings (Forward) | 10.52 |
| Price / Sales | 0.690 |
| Price / Book | 0.930 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -12.97% |
| Operating Margin (TTM) | 7.03% |
| Diluted EPS (TTM) | -5.23 |
| Quarterly Revenue Growth (YOY) | -2.60% |
| Total Debt/Equity (MRQ) | 90.01% |
| Current Ratio (MRQ) | 1.20 |
| Operating Cash Flow (TTM) | 149.30 M |
| Levered Free Cash Flow (TTM) | 297.44 M |
| Return on Assets (TTM) | 1.12% |
| Return on Equity (TTM) | -11.38% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | QuidelOrtho Corporation | Bearish | Bearish |
AIStockmoo Score
0.2
| Analyst Consensus | -0.5 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | 2.0 |
| Average | 0.20 |
|
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 0.92% |
| % Held by Institutions | 112.82% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 33.00 (Citigroup, 24.15%) | Hold |
| Median | 31.00 (16.63%) | |
| Low | 22.00 (JP Morgan, -17.23%) | Sell |
| Average | 28.67 (7.86%) | |
| Total | 2 Hold, 1 Sell | |
| Avg. Price @ Call | 23.11 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 07 Nov 2025 | 22.00 (-17.23%) | Sell | 20.35 |
| UBS | 06 Nov 2025 | 31.00 (16.63%) | Hold | 21.26 |
| Citigroup | 07 Oct 2025 | 33.00 (24.15%) | Hold | 27.71 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BUSKY JOSEPH M. | 26.58 | - | 4,770 | 126,787 |
| WIDDER KENNETH J | - | 28.14 | -4,026 | -113,292 |
| WILKINS JOSEPH D JR. | 27.50 | - | 370 | 10,175 |
| Aggregate Net Quantity | 1,114 | |||
| Aggregate Net Value ($) | 23,670 | |||
| Aggregate Avg. Buy ($) | 27.04 | |||
| Aggregate Avg. Sell ($) | 28.14 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WILKINS JOSEPH D JR. | Director | 26 Nov 2025 | Buy (+) | 370 | 27.50 | 10,175 |
| WIDDER KENNETH J | Director | 25 Nov 2025 | Sell (-) | 4,026 | 28.14 | 113,292 |
| WIDDER KENNETH J | Director | 25 Nov 2025 | Option execute | 7,021 | - | - |
| BUSKY JOSEPH M. | Officer | 24 Nov 2025 | Buy (+) | 4,770 | 26.58 | 126,787 |
| Date | Type | Details |
|---|---|---|
| 24 Nov 2025 | Announcement | QuidelOrtho To Participate In Upcoming Investor Conferences |
| 20 Nov 2025 | Announcement | The Power of Prevention: Detecting Diabetes Before It Strikes |
| 05 Nov 2025 | Announcement | QuidelOrtho Reports Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Announcement | QuidelOrtho Receives FDA 510(k) Clearance for VITROS™ Immunodiagnostic Products hs Troponin I Assay |
| 23 Oct 2025 | Announcement | Informatics Illuminated: Science Bytes Podcast Explores the Power Behind Smarter Diagnostics |
| 22 Oct 2025 | Announcement | QuidelOrtho to Report Third Quarter 2025 Financial Results |
| 16 Oct 2025 | Announcement | QuidelOrtho Showcases Leadership in Transfusion Medicine at AABB 2025 |
| 25 Sep 2025 | Announcement | Through Shades of Illness: Science Bytes Podcast Discusses Why Testing Matters |
| 22 Sep 2025 | Announcement | QuidelOrtho Announces Availability of QUICKVUE™ Influenza + SARS Test for Professional Use |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |